A consensus statement for safety monitoring guidelines of treatments for major depressive disorder

Seetal Dodd, Gin S. Malhi, John Tiller, Isaac Schweitzer, Ian Hickie, Jon Paul Khoo, Darryl L. Bassett, Bill Lyndon, Philip B. Mitchell, Gordon Parker, Paul B. Fitzgerald, Marc Udina, Ajeet Singh, Steven Moylan, Francesco Giorlando, Carolyn Doughty, Christopher G. Davey, Michael Theodoros, Michael Berk

Objective: This paper aims to present an overview of screening and safety considerations for the treatment of clinical depressive disorders and make recommendations for safety monitoring.

Method: Data were sourced by a literature search using MEDLINE and a manual search of scientific journals to identify relevant articles. Draft guidelines were prepared and serially revised in an iterative manner until all co-authors gave final approval of content.

Results: Screening and monitoring can detect medical causes of depression. Specific adverse effects associated with antidepressant treatments may be reduced or identified earlier by baseline screening and agent-specific monitoring after commencing treatment.

Conclusion: The adoption of safety monitoring guidelines when treating clinical depression is likely to improve overall physical health status and treatment outcome. It is important to implement these guidelines in the routine management of clinical depression.

Australian and New Zealand Journal of Psychiatry 2011; 45:712–725
DOI: 10.3109/00048674.2011.595686

© 2011 The Royal Australian and New Zealand College of Psychiatrists
Major depressive disorder (MDD) afflicts an estimated 16% to 20% of the population during their lifetime [1–3]. In Australia 3.1% of men and 5.1% of women are affected in any 12-month period [4]. Current treatments include pharmacological, psychological and physical therapies. Antidepressants are amongst the most commonly prescribed classes of drugs [5] and their use continues to grow [6]. Adverse outcomes are part of the landscape in prescribing medications and therefore management of safety issues need to be an integral part of practice.

The adverse effects of antidepressants vary between individual drugs and drug classes and have been extensively documented [7–9]. In general tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) are associated with more severe adverse effect profiles than the newer antidepressants. MAOIs interact with dietary tyramine necessitating patient counselling about dietary risks [10]. While there is substantial intra-variation in tolerability, MAOIs and TCAs retain an important place in the management of refractory depression [10] and the more putatively biological depressive disorders such as melancholia [11]. The selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and noradrenaline reuptake inhibitors (SNRIs) broadly have lower toxicity than older agents [12], but have also been associated with significant adverse effects including cardiovascular effects, sexual dysfunction [8], weight gain [13], electrolyte disturbances, haematological effects [8] and hepatic damage [14]. A possible increase in suicidal thoughts and self-destructive behaviour in paediatric patients prescribed antidepressants has been documented [15] and regulatory warnings have been extended for young people up to the age of 25 years [16]. Most treatment guidelines recommend clinician vigilance for adverse symptoms or caution when administering antidepressants to people from high risk populations, including those with a prior history of medication sensitivity, the medically unwell [17], the elderly [18], adolescents [19] and pregnant or breastfeeding women [20]. Specific recommendations are, however, not widely available.

MDD is frequently comorbid with physical problems and illnesses including obesity [21], cardiovascular disease and diabetes mellitus [22], substance misuse and other mental disorders, reflecting both antecedent and consequence pathways [23]. This may affect the efficacy of treatments for MDD as well as increasing the vulnerability of patients to adverse effects and risk of harmful drug interactions.

Non-pharmacological treatments for MDD including psychotherapy [24] have also been associated with adverse events. Such adverse effects are, however, less frequently reported. Complementary and alternative treatments can be associated with adverse events [25] and pharmacological interactions. Even exercise, which has an established evidence base in depression treatment [26], may be associated with adverse effects in individuals with comorbid cardiovascular disease, prolonged QT interval or who attempt strenuous activity without a period of adjustment [27]. However, gradual exercise training for rehabilitation following a major cardiac event in depressed individuals is associated with 73% reduced mortality when compared to depressed individuals who did not participate in exercise training [28].

Guidelines exist for safety monitoring of treatments for schizophrenia [29], bipolar disorder [30] and for specific medications (e.g. clozapine) [31], but there are none for clinical depression. Previous Australian guidelines focus on treatment algorithms [32]. Guidelines for baseline screening and safety monitoring of antidepressant treatments may significantly reduce risks of adverse events.

**Method**

Data were sourced by a literature search using MEDLINE and a manual search of scientific journals to identify relevant articles. Searches were conducted on multiple occasions by individual co-authors. Draft guidelines were prepared and serially revised in an iterative manner until all co-authors gave final approval of content. The process was completed over an 18 month period in 2010 and 2011.

**The decision to treat**

The management of depression should include an appropriate diagnostic work up, especially to exclude organic or self-limiting determinants. A person’s individual risk, prior treatment history and therapeutic preferences should be assessed prior to treatment selection. Choice of treatment must carefully balance efficacy, potential harms and patient preference, facilitating an informed choice for patients to treatment that best matches their presentation [33]. The following sections will address evidence-based pre-treatment screening and monitoring of treatment of depression and are shown in Table 1. Baseline screening and monitoring recommendations for specific depression augmentation strategies (e.g. lithium [30], the atypical antipsychotics [29]) are reviewed extensively elsewhere and hence are not included below. Similarly, monitoring of psychological therapy is beyond the scope of this paper [24].
Baseline screening prior to commencement of treatment

Patient history and physical examination

Obtaining a thorough patient history and examination prior to commencing treatment is important in order to (i) determine whether medical factors may be influencing the current presentation, (ii) determine and document any risk factors which may increase susceptibility to adverse outcomes, (iii) establish baseline measures of physical and mental health in order to monitor treatment efficacy and safety, and (iv) clarify depressive type and assist treatment selection.

Specific medical history information that can impact on monitoring and influence outcome includes substance use (e.g. alcohol [34], tobacco [35,36] and prescribed and illicit drugs), physical activity [37,38], life events, diet [39,40] and chronic and medical illness [41] as well as family history, history of illness and treatment history [42]. Personal or family history of thyroid, cardiac and cerebrovascular disease, hypertension, dyslipidaemia and/or diabetes mellitus should alert clinicians to increased risks associated with antidepressant treatments, and guide targeted baseline assessments.

Although uncommon, organic causes of depressive symptoms should be considered and evaluated before treatment is initiated. Organic causes include metabolic disorders, some vitamin deficiencies (e.g. vitamin D [43, 44], folate, B12, magnesium [45], zinc [46]), chronic pain, sleep apnoea, cancer, cerebrovascular disease, neurological disorders, traumatic brain injury, autoimmune disease (systemic lupus erythematosus), some infections (hepatitis and HIV) and endocrine disorders [47]. Thyroid disease is an occasional medical cause of depressive symptom onset or persistence whilst Cushing’s and Addison’s disease are rare causes [48].

Blood and serological testing

Some organic causes of depressive symptoms can be detected through routine blood screening. The following tests may have a role in baseline screening prior to antidepressant treatment.

Thyroid stimulating hormone (TSH) and thyroid hormones

Hyperthyroidism and hypothyroidism can be associated with mood disorders. Symptoms of hyperthyroidism include dysphoria, anxiety, restlessness, emotional lability and impaired concentration. Symptoms of hypothyroidism include psychomotor retardation, decreased appetite, fatigue and lethargy, which when severe mimics melancholic depression [48]. Subclinical and past thyroid dysfunction is a risk factor for depression and antidepressant non-response [49]. Identification of abnormal thyroid function in depressed patients should prompt correction of thyroid hormone levels (T3 and T4), and where necessary, referral to an endocrinologist for further investigation. Depressive symptoms may resolve with correction of thyroid hormone levels. However, for some patients depressive symptoms may persist and require additional treatment.

Full blood examination (FBE)

Full blood examination (FBE) can identify anaemia, potential underlying infections and blood dyscrasias that may contribute to depressive symptoms. Anaemia can induce fatigue and may be misinterpreted as, or contribute to, depressive symptoms. Alterations in leucocytes may alert to the presence of an underlying infection or other pathological process (e.g. cancer).

Liver function tests

Diseases of the liver have been associated with depression [50], and some antidepressant treatments are associated with hepatotoxicity [14]. Impaired liver function at baseline should prompt further investigation to determine and treat any hepatic disease. High levels of GGT and AST may suggest comorbid alcohol abuse, especially if concurrent with an increased mean cell volume [51]. Intravenous drug use may result in hepatitis C and cause abnormal liver function tests (LFT).

Screening for viral and other infections

Viral infections including human immunodeficiency virus (HIV) [52], hepatitis C [53], West Nile virus [54] and Epstein-Barr virus [55, 56] are associated with depression, albeit uncommonly. This may relate directly to the infection or be consequent to elevated levels of cytokines that may themselves be biomarkers of risk for depression [57]. Fatigue is common following acute infective illness [58] and may be mistakenly attributed as a depressive symptom. In addition, antiviral treatment, most notably PEGylated interferon, can cause episodes of depression [59]. Though uncommon in contemporary practice, non-viral infections such as syphilis [60] can also cause depressive symptoms. Fatigue and depressive symptoms may be a response to activation of the immune system [61], suggesting that broader associations between infections, treatments for infections and the manifestation of depressive symptoms may exist. Prior to commencing antidepressants, a detailed history of past infectious illness and treatments should be acquired, and
or withdrawal can be confused with a mood disorder [65]. Furthermore, comorbid alcohol or substance abuse are associated with antidepressant treatment resistance and non-adherence [66]. Obtaining a detailed drug and alcohol history is essential in patients with depression, although clinicians should be cognisant of potential underreporting. Blood or urine screening may be useful in selective cases although such screening only identifies substances present at the time of the test. Collateral information from relatives and friends, as well as other health professionals is invaluable to fully explore substance and alcohol issues. Raised transaminases, elevated carbohydrate deficient transferrin and increased mean cell volume are a clue as to the presence of alcohol abuse.

Screen for prescription medications

Several medications are known to induce depressive symptoms. Interferon and other immune active agents supplemented with serological testing and testing of inflammatory markers (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)) if current infection is suspected.

### Alcohol and illicit substance screen

Alcohol abuse or dependence are causal factors contributing to depression [62]. Many other substances have also been associated with depression; however, the direction of causality has not been clearly determined. Smoking can increase the risk of depression [35], through direct neurotransmitter mechanisms and via pharmacokinetic drug interactions (e.g. tar components inducing hepatic isoenzymes CYP1A1, CYP1A2 and possibly CYP2E1) and pharmacodynamic drug interactions with nicotine [63]. Depressive symptoms may also emerge with smoking cessation [64]. Cannabis, amphetamine and cocaine use are also associated with depression, and intoxication or withdrawal can be confused with a mood disorder [65].

### Table 1. Monitoring recommendations for patients treated for major depressive disorder

| Monitoring parameter                                      | Agent                                      | Frequency                                      | Comments                                                                                     |
|-----------------------------------------------------------|--------------------------------------------|------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Electrocardiogram for QT prolongation                     | Tricyclic antidepressants                  | Baseline, after initial dose titration and at dose changes | More caution is indicated in children and the elderly and at higher doses                      |
| Liver function test                                       | Agents with hepatic liability              | At the start of treatment and at 6, 12 and 24 weeks of treatment and when clinically indicated | Mandated for agomelatine, other agents as indicated                                             |
| BMI and waist circumference                               | Agents with known weight gain liability    | Baseline at one month and at 6 month intervals | More caution with mirtazapine, mianserin, tricyclics and MAOIs                                |
| Vitamin D, B12, folate, zinc, magnesium                   | All antidepressants                        | Baseline                                      | If indicated                                                                                 |
| Electrolytes for hyponatraemia                            | SSRIs, mirtazapine, SNRIs and TCAs         | At baseline and after one month if clinically indicated in high risk groups, especially the elderly (> 65 years) | More frequent monitoring in elderly or those with existing hyponatraemia, follow up testing of urine and serum osmolality |
| Full Blood Examination to detect neutropaenia and thrombocytopaenia | Mirtazapine and mianserin | If clinically indicated |                                                                                  |
| Suicidality                                               | All antidepressants, especially SSRIs in adolescents | Weekly in the first few weeks of treatment. More frequent monitoring may be required in more severely depressed or suicidal patients | Particular caution in adolescents Warn next of kin/carer and ask for their collateral monitor as well |
| Antidepressant side-effect monitoring or Checklist        | All antidepressants                        | At one month and with reviews                 |                                                                                  |
| Bone mineral density                                      | SSRIs                                      | As clinically indicated in high risk groups    |                                                                                  |
| Blood pressure monitoring                                 | Venlafaxine, tricyclics and MAOIs         | With venlafaxine, tricyclics and MAOIs; at baseline, and with significant dose increase and 3-6 monthly after stabilization | Closer monitoring of MAOI’s in first weeks (tolerance occurs) |
(previously mentioned) may be directly causative of depressive episodes [59]. Benzodiazepine use may be associated with depression [67]. Opiates are frequently utilized agents especially in the context of chronic pain. Depression and chronic pain are commonly comorbid and iterative, and it is possible that chronic opiate use has a noxious effect on mood [68,69]. Other potential mood modifying agents include some steroidal and other hormonal treatments [70,71], cardiovascular drugs, cholesterol lowering agents, parkinsonian agents, antibiotic agents [72], antineoplastic agents [73], anticonvulsants [74], typical antipsychotics and analgesics [75–78]. If there is a temporal association of the onset of depression and the commencement of a medication, then an assumption of causality is practicable.

**Vitamin D**

A high prevalence of vitamin D insufficiency is found in most western societies [79] particularly amongst the elderly [80–83]. Psychiatric cohorts appear to have even higher rates of Vitamin D insufficiency [43], with 58% of inpatients in one study having vitamin D insufficiency and 11% showing deficiency. Low levels of vitamin D, which are common in winter, may contribute to seasonal affective disorder (SAD) [84,85] and a higher likelihood of developing a depressed mood [86,87]. There are some data, albeit inconsistent, that vitamin D supplementation may prevent or improve depressive symptoms [88,89]. While a comprehensive picture of the role of vitamin D in depression is yet to emerge, the high yield from screening and the simplicity of supplementation suggests that screening may be worthwhile. There is some evidence that folate, vitamin B12 magnesium and selenium, amongst other nutrients, are deficient in some individuals with depression, and inconsistent data that supplementation may be of value [45,90–92]. The absence of quality data limits evidence-based recommendations regarding screening, but this should be considered if indicated by history.

**Cognitive neuropsychological testing**

Depression often overlaps with dementia and mild cognitive impairment in elderly patients. Late onset depression may be a prodrome of cognitive decline [93] and depressive symptoms can be confused with dementia [94]. In patients with late-onset depression, diagnostic work up may require formal assessment of cognitive impairment. Late onset vascular depression has been associated with brain small vessel disease demonstrated by hyperintensities on MRI scans [95]. Patients with consistent symptoms should be assessed for vascular risk factors such as smoking, hypertension and diabetes.

**Metabolic profile, waist circumference and body mass index**

Many antidepressants are associated with weight gain, but depression, particularly atypical depression, can cause weight gain independent of medication [21,96]. Metabolic syndrome is a cluster of risk factors which identify individuals at high risk for cardiovascular disease and type II diabetes mellitus [97]. The prevalence of metabolic syndrome in patients with current major depression was found to be 56% in a Finnish study [98] and 25% in a German study [99]. The relationship between depression and metabolic syndrome is bidirectional, with the syndrome also predictive of increased risk for depression [100]. A study of depressed inpatients recommended baseline metabolic screening for all hospitalized depressed patients and re-screening during remission [99]. Baseline measurements of height, weight (to calculate body mass index) and waist circumference should be undertaken. Patients should be questioned about risk factors for metabolic syndrome including smoking, personal or family history of diabetes, while observational analysis will also commonly suggest those at high risk or likelihood of the syndrome or its complications, such as sleep apnoea. Where appropriate, advice regarding smoking cessation should be given. Guidelines for reviewing risk factors for metabolic syndrome during antidepressant treatment are given in the section detailing ongoing monitoring.

**Cardiovascular disease**

People with depression are at an increased risk of developing cardiovascular disease [101]. In addition, some antidepressants (in particular TCAs) have associated adverse cardiovascular effects, although most of the newer antidepressants demonstrate low cardiotoxicity. TCAs may affect cardiac conduction and should be used with caution in patients with pre-existing cardiac disorders (especially in those with recent myocardial infarction and arrhythmias) [102]. Although rare, case reports of adverse cardiac events with newer antidepressants exist, including atrial fibrillation associated with fluoxetine treatment [102] and mild bradycardia with fluoxetine, fluvoxamine and paroxetine [12]. Adverse cardiac events usually occur in patients with additional risk factors such as smoking [103]. An ECG is probably indicated at baseline and after attainment of therapeutic dosage in individuals with clinical risk factors who have been prescribed agents that can alter the ECG, particularly TCAs. Baseline monitoring of blood pressure and pulse is useful and particularly important if a MAOI or TCA is prescribed [104]. Venlafaxine can cause
tachycardia and increased blood pressure, and this merits monitoring [105]. Postural hypotension is particularly common with the MAOIs early in the treatment course, although tolerance typically develops. Antidepressant treatment may cause changes in cardiac function that are not outside the clinically normal range [12], therefore baseline measurements will be required to detect these changes.

**Twenty-four-hour urinary free cortisol**

Hypercortisolaemia and hypocortisolaemia are both associated with depression, although patients typically present with different symptom clusters. Hypocortisolaemia may be more likely to be associated with ‘atypical’ depression, with symptoms including hypoarousal, hypersonomnia, hyperphagia, lethargy, pain, fatigue and relative apathy, whereas hypercortisolaemia may be associated with ‘typical’ symptoms such as hyperarousal, anxiety, insomnia and loss of appetite [106]. It is unclear whether hypothalamic-pituitary-adrenal (HPA) axis activation is causative of depression and consequently information about plasma cortisol is of limited clinical use. The exception is hypercortisolaemia associated with Cushing’s syndrome, where depressive symptoms are common and may improve with treatment of the endocrine disorder [106]. Endocrine and cytokine dysfunction often co-occur [107], which may also influence mood disturbances. A cushingoid appearance, impaired glucose tolerance and electrolyte disturbance may point to this diagnosis, and a 24-h urinary free cortisol measurement prior to commencing antidepressant therapy may be useful in this scenario.

**Pregnancy testing**

Screening for pregnancy, including detailed history and consideration of a pregnancy test where indicated is important for women of childbearing age. Pregnancy can influence mood, especially when associated with psychosocial stressors such as an absent partner or when the pregnancy is unplanned [108]. Pregnancy also raises issues of potential drug-induced teratogenicity; hence knowledge of pregnancy status is important for guiding treatment choices [20,109,110].

**Genetic testing**

Pharmacogenetics (genotype associations to medication response and tolerability) is an emerging area of promise in the safer and more effective prescription of various medications. Some pharmacogenetic tests are commercially available while others are still at an experimental stage. Typically, the tests either probe for polymorphisms of genes involved in neurotransmitter function or probe for polymorphisms of genes involved in drug metabolism [111]. Currently, the role of genotyping to predict antidepressant adverse effects remains unclear. While there is evidence that genotyping cytochrome P450 polymorphisms detects poor metabolisers and ultra-rapid metabolizers with some level of accuracy, their clinical utility in dose finding remains under investigation [112,113]. At present there is no evidence supporting the use of these genetic tests in routine clinical practice, particularly as there is no demonstrated relationship between blood concentrations of the SSRIs or other new antidepressants and clinical efficacy. The role of blood-brain barrier pump polymorphisms is also being explored [114]. There is limited evidence that certain genotypes are associated with higher rates of emergent suicidality while receiving an antidepressant, but results remain mixed [115]. At this stage, routine genetic testing of patients commencing antidepressants does not appear to have sufficient evidence to guide recommendations. In selected patients with a history of medication sensitivity or resistance, there may be a limited place for CYP450 genotyping. Should robust evidence of predicting pharmacogenetic response, tolerability and safety associations emerge there may be a greater place for such genotyping in the future.

**Neuroimaging**

Neuroimaging has advanced substantially in the past three decades, with current technology permitting the assessment of neurochemical concentrations within the brain, more detailed appreciation of its structure and connections and an intriguing insight into its functionality. However, a lack of a consensus as regards diagnostic criteria and clinical phenotype of depression has meant that the emergence of characteristic neuroimaging features that have the necessary sensitivity and specificity at an individual level is yet to occur [116]. The only exception to this may be the use of MRI in cases of late onset depression to confirm the presence of underlying causative small vessel disease. Late onset depression may at times progress to dementia, and MRI will provide a baseline for future assessments.

**Screening for electroconvulsive therapy**

In most jurisdictions, electroconvulsive therapy (ECT) is subject to specific legislative constraints and treatment needs to respect these limitations [117]. Patients should be assessed, including relevant investigations into their
general physical health prior to receiving ECT. Acutely ill patients should only receive ECT as an inpatient, at least until their condition stabilizes, as suicide risk may increase in the early phase of treatment [118]. Investigations should be tailored to the individual patient depending on their history, physical examination and diagnosis. Screening for ECT overlaps considerably with pre-anaesthetic screening and general recommendations in this document.

Uncontrolled hypertension and cerebral tumours are absolute contraindications to ECT. Blood pressure must be assessed. Cochlear implants are a contraindication, unless removed. Cardiac pacemakers are not a contraindication, but it is essential to know the underlying cardiac rhythm and to liaise with the patient’s cardiologist on pacemaker management with ECT. Cardiologist opinion should also be sought with patients who have severe aortic stenosis. Anaesthetic monitoring includes ECG, pO2 and pCO2, and respiratory rate monitoring of pO2 and pCO2, as well as pulse, blood pressure, respirations, and conscious state are critical in the recovery area.

Biomarkers

An emerging research area is that of biomarkers in depression. New data suggest certain biomarkers, including cytokines such as CRP [128] and leptin [129], may be indicative of risk of development of de-novo depression. Other biomarkers have demonstrated a cross-sectional association with depression, such as measures of oxidative stress and neurotrophins [130]. These markers are currently of research interest only, while provisional evidence suggests potential roles they may shed light on clinical course and outcome [131], data are too preliminary to merit incorporation in routine clinical screening.

Ongoing monitoring during antidepressant treatment

Suicide

After initiating antidepressant treatment, patients should be monitored for suicide risk. A thorough review of suicide monitoring is beyond the scope of this review, however practice guideline are available elsewhere [119, 120].

Obesity and metabolic syndrome

Waist circumference and body mass index should be monitored, particularly in patients treated with antidepressants associated with weight gain [121]. It is unclear whether being overweight at baseline is associated with further weight increase with antidepressant exposure. Most studies have found no clear association between antidepressant-induced weight gain and baseline measures [122]. In some cases antidepressant treatment may reduce weight and abdominal fat by decreasing anxiety and regulating dietary patterns [123]. A naturalistic study found that weight gain in the first week of antidepressant treatment was a significant predictor of sustained weight gain [13]. There is limited evidence that ethnicity may influence weight increases with antidepressant treatment [124]. Early detection of weight gain and intervention to prevent sustained weight gain may have significant benefits. Monitoring of the metabolic profile may be prudent at 3, 6 and 12 months, then yearly, in all patients, not just in patients who are obese or overweight.

While TCAs, MAOIs, mianserin and mirtazapine are most associated with weight gain [121], problems may arise with other newer antidepressants. Paroxetine may be more likely to cause weight gain than other SSRIs, and bupropion may be less likely than the SSRIs [125]. Particular attention should be given to those patients receiving augmentation or combination pharmacotherapy, especially with atypical antipsychotics [126].

Cardiovascular status

Cardiovascular status may need monitoring during antidepressant treatment. Electrocardiography (ECG) is recommended for patients being treated with the older antidepressants, especially in those over 45 years of age and those with cardiovascular disorders [12]. ECG should be considered prior to initiation of a TCA, and at steady state, for monitoring the QTc interval and for development of arrhythmias [127]. It may also be considered prior to commencing treatment with an SNRI in high-risk individuals. QT prolongation is a common finding in the elderly. It can lead to Torsades de Pointes (a re-entrant tachycardia), resulting in ventricular fibrillation and sudden cardiac death. It is possible that such outcomes are under-reported. TCAs are known to cause QT prolongation by autonomic effects and effect on rapid outward potassium currents, resulting in delayed repolarization. Patients who have already been treated with a class I antiarrhythmic agent (Na+ channel blocking) [12] and those who metabolize tricyclics more slowly (cytochrome CYP2D6 poor metabolizer phenotype) may be at increased risk [128]. Electrolyte disturbances, which can be a consequence of some antidepressants, increase the risk of arrhythmias [129]. SSRIs have also been rarely associated with cases of Torsades de Pointes. There were 20 such cases associated with fluoxetine, with one fatality, reported by WHO adverse drug effect monitoring between 1983 and 1999 [130]. Cases associated with SSRIs, however, remain...
in frequent, sporadic and often involve overdose or drug interactions. Overdose of tricyclics and SSRIs mimic the appearance of Brugada’s syndrome with right bundle branch block and ST elevation [131], suggesting some drugs (including fluoxetine and amitriptyline) may also block cardiac sodium channels. Baseline ECG is important in excluding familial long QT syndrome and to reveal T or U wave abnormalities. Repeat ECG monitoring of QT prolongation may be indicated when significant dose changes are made with TCAs. ECG monitoring with SSRI treatment may be useful in high risk cases, though this is usually unnecessary.

Blood dyscrasias

There are rare reports of blood dyscrasias with antidepressant administration. Case reports have included mianserin- or mirtazapine-induced neutropenia [132] and citalopram-induced thrombocytopenia [133]. Agranulocytosis induced by newer antidepressants is much less common than that which was reported with tricyclic or tetracyclic antidepressants [8]. Monitoring of the full blood examination in patients treated with antidepressants may be prudent when rechallenging patients with a history of a blood dyscrasia. With mirtazapine and mianserin, one should be alert for emergent symptoms such as fever, sore throat, stomatitis or other signs of infections. If such symptoms occur, haematological investigations should be undertaken and the treatment stopped. Given the very low yield of screening for this very rare adverse event, routine haematological monitoring is not justified.

Hepatotoxicity

Numerous antidepressants have been found to affect the liver. The MAOIs and the TCAs are associated with an appreciable though infrequent risk of hepatotoxicity [134]. However, changes in hepatic enzyme levels have rarely been reported for SSRIs and other newer antidepressants including paroxetine [135–137], sertraline [138,139], fluoxetine [140,141], mianserin [142], mirtazapine [143,144], bupropion [145], trazodone [146,147], nefazodone [14], venlafaxine [146], duloxetine [148] and agomelatine [149]. Disentangling these rare reports from baseline-associated factors is difficult. Antidepressant-induced hepatotoxicity is usually an idiosyncratic adverse drug reaction of low prevalence characterized by elevated ALT and sometimes by jaundice. The consequences of antidepressant-induced changes in hepatic function can range from asymptomatic changes [144] to fatal outcomes [145]. It is unclear whether the use of antidepressants may aggravate existing hepatic disease. Pre-existing hepatic disease may alter the metabolic clearance of some antidepressants and may necessitate dose adjustment [134].

It does not appear that susceptibility to antidepressant-induced hepatotoxicity can be predicted by LFT or ALT before commencing antidepressant treatment. Therefore these tests are not used as a baseline screen to monitor risk for developing de-novo hepatic injury in response to antidepressant exposure [134]. However, they may be useful for detecting pre-existing hepatic injury and for establishing a baseline for patients before commencing antidepressant treatment and are required before commencing treatment with agomelatine. Antidepressant-induced hepatotoxicity typically occurs within the first few months of treatment.

Nefazodone has been withdrawn from the Australian market as a result of cases of fatal hepatotoxicity [150,151]. Elevations of serum transaminases are documented in clinical trials of agomelatine but these changes usually return to normal levels after discontinuation. The European Medicines Agency has recommended a liver function test for patients treated with agomelatine at the start of treatment and at 6, 12 and 24 weeks of treatment and when clinically indicated [152].

Lucena et al. [134] state that hepatotoxicity is an uncommon and unpredictable idiosyncratic reaction, and that there is no evidence that routine monitoring reduces the rate of hepatotoxicity with antidepressants in general.

After a hepatotoxic reaction, if an antidepressant rechallenge is indicated, monthly liver functions test for the first 6 months of treatment, with discontinuation of treatment if ALT values exceed (by three times) the upper limit of the normal range, if bilirubin levels rise, or if signs or symptoms of liver dysfunction are present, are recommended by the authors. If an individual develops increased serum transaminases, tests should be repeated within 48 h. After discontinuation, monitoring can be continued to ensure that liver function returns to the normal range. Rechallenge should be considered with caution, and only after careful consideration of risks and benefits. Adverse reactions to an antidepressant rechallenge are not uncommon [150] and sometimes a more severe antidepressant-induced hepatotoxic reaction may occur following antidepressant rechallenge [139,153].

Hyponatraemia

SSRIs and some other antidepressants have been reported to cause hyponatraemia. The incidence rate in the elderly is 4.7 cases/1000 people treated/year [154,155], but is much lower in younger age groups. It should be suspected if an elderly patient becomes confused or develops a frank delirium after commencement of an antidepressant. It may be why a person’s mood may inexplicably worsen. Deaths associated with
hyponatraemia have been reported [156]. Liu et al. [157] reported on 736 cases between 1980 and 1995 associated with fluoxetine, fluvoxamine, paroxetine and sertraline use. Hyponatraemia has also been reported for citalopram [158], escitalopram [159], duloxetine [160], mirtazapine [161] and reboxetine [162]. It has been suggested that the risk may be greatest for patients who take fluoxetine compared to other antidepressants [154]. SSRIs can induce isovolemic hyponatraemia through a syndrome of inappropriate anti-diuretic hormone (SIADH) secretion [159]. Hyponatraemia can resolve with antidepressant discontinuation and reoccur with rechallenge [160]. Baseline screening of patients should include an assessment of risk factors for antidepressant-induced hyponatraemia including advanced age (>65 years) [157], previous history of antidepressant-induced hyponatraemia [160], low body weight [155], thiazide use [163], and the use of other agents that may cause hyponatraemia such as carbamazepine [164]. Anecdotally, female gender [163] may also be a risk factor. Most cases of hyponatraemia occur within the first 10 weeks of initiating antidepressant treatment, with 79% occurring in the first 3 weeks [154]. Regular monitoring of serum sodium in elderly patients has been recommended by some clinicians [154]. SIADH may also cause a worsening of depressive symptoms [154,159] and therefore should be sought and excluded. SIADH should be investigated if a person reports clinical deterioration, cognitive change or dizziness and fatigue after initiation of antidepressant treatment [159]. There is no current protocol for monitoring serum sodium in patients being treated with antidepressants; however, monitoring after 3-4 weeks of treatment should occur in individuals who match the high risk profile [155].

Bone mineral density

There are recent data indicating that SSRIs may reduce bone mineral density [165]. Serotonin has a key signalling role in bone cells and influences bone metabolism. Williams et al. showed a loss of 6.2% of bone mineral density (BMD) with SSRI treatment [166]. This magnitude of bone loss has the potential to lead to a 20% increased fracture risk. Bolton et al. described SSRI use in older adults being associated with an increased odds of osteoporotic fractures (OR = 1.45), as for other monoamine antidepressants (OR = 1.15), although the relationship was weaker [167]. These data are supported by a study showing that the risk of non-vertebral fracture for those over 55 years was two-fold for current users of SSRIs compared with non-users of antidepressants [168]. Preliminary data suggest intra-class differences [169], with citalopram seeming to have the lowest impact on osteoblast and osteoclast function. There are data indicating that, independent of treatment, people with depression have lower bone mineral density and a higher fracture risk, which is likely to be a compound result of lifestyle factors, disease state and iatrogenic treatment effects. These disease-related effects, combined with the effects on treatment, suggest that screening for bone mineral density should be considered in people on long-term SSRIs, and particularly in high risk groups such as the elderly, women and those with other risk factors such as fracture history, history of falls, low vitamin D, hypogonadism, hyperparathyroidism, thyroid dysfunction, systemic inflammatory disorders, and corticosteroid use. Physical inactivity, alcohol use and smoking are shared lifestyle risk factors for both depression and low BMD.

Other adverse effects

Antidepressant treatment is commonly associated with milder adverse effects. The Antidepressant Side-Effect Checklist itemizes 21 adverse events; nausea or vomiting, sexual dysfunction, increased appetite, decreased appetite, sweating, increased body temperature, weight gain, dry mouth, drowsiness, insomnia, blurred vision, headache, constipation, diarrhoea, problems with urination, palpitations, orthostatic dizziness, vertigo, tremor, disorientation, and yawning [9]. Such adverse effects are important causes of non-adherence to antidepressant treatment [9] and should therefore be routinely monitored.

Drug–drug interactions

Monitoring should take into account that antidepressants may interact with other medications and reduce the therapeutic effect or increase side-effects. Perhaps one of the most important differences between the newer antidepressants is their varying potential to cause drug–drug interactions through inhibition of cytochrome-P450 (CYP) enzymes [170]. Fluvoxamine, a potent inhibitor of CYP1A2 and CYP2C19, is a particular cause for concern with clinically relevant interactions reported with caffeine, clozapine, benzodiazepines, warfarin and other medications [170,171]. SSRIs such fluoxetine and paroxetine, which are potent inhibitors of CYP2D6, can also produce relevant interactions with other medications including beta-blockers, tricyclic antidepressants and antipsychotics such as perphenazine [172]. Special attention should be given to fluoxetine because inhibitory effects can persist for up to five weeks after discontinuation. Sertraline, citalopram and escitalopram seem to have less interaction potential than the other SSRIs [170,173]. Duloxetine and bupropion are moderate inhibitors of CYP2D6, while venlafaxine, mirtazapine
Optimal safety monitoring is part of a system of care committed to a culture of patient safety. The treating clinician is primarily responsible for decisions regarding treatment choice, making these decisions on the basis of shared decision making, in the context of a collaborative alliance, and communicating the risks and benefits to the patient. In divergent settings, the monitoring arrangements need to vary. Computerized electronic medical records or checklists with reminder prompts may help with safety monitoring; however, systems for lines of communication, co-ordination of monitoring practices and for the interpretation of results need to be developed. If adverse events emerge, the re-balanced risk–benefit ratio needs to be evaluated on an individual basis. Decisions regarding further investigations, referrals to specialist care or the need for treatment changes will need to be made.

Safety monitoring guidelines are developed from indirect data, which are frequently limited and drawn from clinical trial data and surveillance monitoring. Almost no direct studies are available on the utility, cost–benefit ratios, yield or practical implementation of safety monitoring guidelines. The guidelines themselves are the product of an imperfect process of literature review moulded by consensus opinion. They therefore need to be used flexibly and should be moulded by clinical acumen. The recommendations should be adapted to the needs of individual patients, taking into account broad risk factors such as age, general health, comorbidity, polypharmacy, capacity for adherence to monitoring procedures, and clinical diagnosis. It needs to be stressed that these guidelines do not represent a fixed standard of care in a medico-legal context. The principal goal of these guidelines is to increase the probability of prompt detection and intervention for relatively insidious but clinically significant adverse events. They are likely to evolve with further research on risk, tolerability and safety of treatments.

**Declaration of interest:** This paper was completed under the auspices of the Australasian Society for Bipolar and Depressive Disorders. It was supported by an unrestricted grant from Servier Laboratories (Australia) Pty. Ltd. 8 Cato Street, Hawthorn VIC 3122, Australia to M.B and S.D. However, at no point in the process of planning, synthesis and writing was there any input or involvement from Servier. The authors alone are responsible for the content and writing of the paper.

**References**

1. Heo M, Murphy CF, Fontaine KR, Bruce ML, Alexopoulos GS. Population projection of US adults with lifetime experience of depressive disorder by age and sex from year 2005 to 2050. *Int J Geriatri Psychiatry* 2008; 23:1266–1270.
2. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA* 2003; 289:3095–3105.
3. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies. *Eur Neuropsychopharmacol* 2005; 15:357–376.
4. Slade T, Johnston A, Oakley Browne MA, Andrews G, Whiteford H. 2007 National Survey of Mental Health and Wellbeing: methods and key findings. *Aus N Z J Psychiatry* 2009; 43:594–605.
5. Worthy KC, Governale LA. Trends in outpatient prescription usage in the U.S., 2002 – 2005. Poster presented at the 12th Annual FDA Science Forum, Washington, DC, April 18–20, 2006, board no. I-13.
6. Hollingworth SA, Burgess PM, Whiteford HA. Affective and anxiety disorders: prevalence, treatment and antidepressant medication use. *Aus N Z J Psychiatry* 2010; 44:513–519.
7. Wille SM, Cooreman SG, Neels HM, Lambert WE. Relevant issues in the monitoring and the toxicology of antidepressants. *Crit Rev Clin Lab Sci* 2008; 45:25–89.
8. Magno R, Mahajan R, Thase ME. Medically serious adverse effects of newer antidepressants. *Curr Psychiatry Rep* 2008; 10:249–257.
9. Uher R, Farmer A, Henigsberg N et al. Adverse reactions to antidepressants. *Br J Psychiatry* 2009; 195:202–210.
10. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. *CNS Spectr* 2008; 13:855–870.
11. Parker G, Fink M, Shorter E et al. Issues for DSM-5: whither melancholia? The case for its classification as a distinct mood disorder. *Am J Psychiatry* 2010; 167:745–747.
12. Pacher P, Kesekemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? *Curr Pharm Des* 2004; 10:2463–2475.
13. Himmerich H, Schuld A, Haack M, Kaufmann C, Pollmacher T. Early prediction of changes in weight during six weeks of treatment with antidepressants. *J Psychiatr Res* 2004; 38:485–489.
14. Carvajal Garcia-Pando A, Garcia del Pozo J, Sanchez AS, Velasco MA, Rueda de Castro AM, Lucena MI. Hepatotoxicity associated with the new antidepressants. *J Clin Psychiatry* 2002; 63: 135–137.
15. Culpepper L, Davidson JR, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL. Suicidality as a possible side effect of antidepressant treatment. *J Clin Psychiatry* 2004; 65:742–749.

16. Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. *Am J Psychiatry* 2007; 164:1786–1789.

17. Franco-Bronson K. The management of treatment-resistant depression in the medically ill. *Psychiatr Clin North Am* 1996; 19:329–350.

18. Sommer BR, Fenn H, Pompei P, DeBattista C, Lembke A, Wang P, Flores B. Safety of antidepressants in the elderly. *Expert Opin Drug Saf* 2003; 2:367–383.

19. Berk M, Dodd S. Antidepressants and adolescents: the bipolar confound? *Hum Psychopharmacol* 2005; 20:1–2.

20. Wisnner KL, Sit DK, Hanusa BH et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. *Am J Psychiatry* 2009; 166:557–566.

21. Williams LJ, Pasco JA, Henry MJ et al. Lifetime psychiatric disorders and body composition: a population-based study. *J Affect Disord* 2009; 118:173–179.

22. Turvey CL, Schultz SK, Beglinger L, Klein DM. A longitudinal community-based study of chronic illness, cognitive and physical function, and depression. *Am J Geriatr Psychiatry* 2009; 17:632–641.

23. Maes M, Leonard B, Fernandez A et al. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: From antioxidants to kinase inhibitors. *Prog Neuropsychopharmacol Biol Psychiatry* 2011; 35:659–663.

24. Berk M, Parker G. The elephant on the couch: side-effects of psychotherapy. *Aust N Z J Psychiatry* 2009; 43:787–794.

25. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J. Drug interaction of St John’s wort with cyclosporin. *Lancet* 2000; 355:1912.

26. Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA. Exercise for depression. *Cochrane Database Syst Rev* 2009:CD004366.

27. Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE. Triggering of sudden death from cardiac causes by vigorous exertion. *N Engl J Med* 2000; 343:1355–1361.

28. Milani RV, Lavie CJ. Impact of cardiac rehabilitation on depression and its associated mortality. *Am J Med* 2007; 120:799–806.

29. Marder SR, Essock SM, Miller AL et al. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry* 2004; 161:1334–1349.

30. Ng F, Mammen OK, Wilting I et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. *Bipolar Disord* 2009; 11:559–595.

31. Berk M, Fitzsimons J, Lambert T et al. Monitoring the safe use of clozapine: a consensus view from Victoria, Australia. *CNS Drugs* 2007; 21:117–127.

32. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. *Aust N Z J Psychiatry* 2004; 38:389–407.

33. Malhi GS, Adams D, Porter R et al. Clinical practice recommendations for depression. *Acta Psychiatr Scand Suppl* 2009:8–26.

34. Coulson CE, Williams LJ, Henry MJ et al. Patterns of alcohol use and associated physical and lifestyle characteristics according to new Australian guidelines. *Aust N Z J Psychiatry* 2010; 44:946–951.

35. Pasco JA, Williams LJ, Jacka FN et al. Tobacco smoking as a risk factor for major depressive disorder: population-based study. *Br J Psychiatry* 2008; 193:322–326.

36. Berk M, Ng F, Wang WV et al. Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania. *J Affect Disord* 2008; 110:126–134.

37. Jacka FN, Pasco JA, Williams LJ et al. Lower levels of physical activity in childhood associated with adult depression. *J Sci Med Sport* 2011; 14:222–226.

38. Pasco JA, Williams LJ, Jacka FN et al. Habitual physical activity and the risk for depressive and anxiety disorders among older men and women. *Int Psychogeriatr* 2010:1–7.

39. Jacka FN, Kremer PJ, Leslie ER et al. Associations between diet quality and depressed mood in adolescents: results from the Australian Healthy Neighbourhoods Study. *Aust N Z J Psychiatry* 2010; 44:435–442.

40. Jacka FN, Pasco JA, Myklebut A et al. Association of western and traditional diets with depression and anxiety in women. *Am J Psychiatry* 2010; 167:305–311.

41. Batten P, Christensen H, Mackinnon AJ. Modifiable risk factors predicting major depressive disorder at four year follow-up: a decision tree approach. *BMC Psychiatry* 2009; 9:75.

42. Zautripf NP, Vergouwe Y, King M et al. A clinical prediction rule for detecting major depressive disorder in primary care: the PRE-DICT-FL study. *Fam Pract* 2009; 26:241–250.

43. Berk M, Jacka FN, Williams LJ, Ng F, Dodd S, Pasco JA. Is this D vitamin to worry about? Vitamin D insufficiency in an inpatient sample. *Aust N Z J Psychiatry* 2008; 42:874–878.

44. Berk M, Sanders KM, Pasco JA et al. Vitamin D deficiency may play a role in depression. *Med Hypotheses* 2007; 69:1316–1319.

45. Jacka FN, Overland S, Stewart R, Tell GS, Bjelland I, Myklebust A. Association between magnesium intake and depression and anxiety in community-dwelling adults: the Hordaland Health Study. *Aust N Z J Psychiatry* 2009; 43:45–52.

46. Szewczyk B, Poleszak E, Sowa-Kuczma M et al. Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. *Pharmacol Rep* 2008; 60:585–589.

47. Robertson MM, Katona CLE. *Depression and physical illness*. Chichester: Wiley, 1997.

48. Bauer M, Goetz T, Glenn T, Whybrow P. The thyroid–brain interaction in thyroid disorders and mood disorders. *J Neuroendocrinol* 2008; 20:1101–1114.

49. Fountoulakis KN, Kantartzis S, Siamouli M et al. Peripheral thyroid dysfunction in depression. *World J Biol Psychiatry* 2006; 7:131–137.

50. Carta MG, Hardoy MC, Garofalo A et al. Thyroid dysfunction in depression and physical illness. *Psychiatr Clin North Am* 1996; 19:949–955.

51. Murray KO, Resnick M, Miller V. Depression after infection with West Nile virus. *Emerg Infect Dis* 2007; 13:479–481.

52. Miller AH, Silberstein C, Asnis GM et al. Epstein-Barr virus infection and depression. *J Clin Psychiatry* 1986; 47:529–530.
98. Heiskanen TH, Niskanen LK, Hintikka JJ et al. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 2006; 67:1422–1427.
99. Richter N, Juckel G, Assion HJ. Metabolic syndrome: a follow-up study of acute depressive inpatients. Eur Arch Psychiatry Clin Neurosci; 260:41–49.
100. Takeuchi T, Nakao M, Nomura K et al. Association of the metabolic syndrome with depression and anxiety in Japanese men: a 1-year cohort study. Diabetes Metab Res Rev 2009; 25:762–767.
101. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155:4–11.
102. Murray JB. Cardiac disorders and antidepressant medications. J Psychol 2000; 134:162–168.
103. Khawaja IS, Feinstein RE. Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants. Heart Dis 2003; 5:153–160.
104. O’Brien S, McKeon P, O’Regan M, O’Flaherty A, Patel R. Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline. J Clin Psychopharmacol 1992; 12:104–109.
105. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 2007; 64:192–197.
106. Wolcottiz OM, Burke H, Epej ES, Reus VI. Glucocorticoids. J Clin Psychopharmacol 1992; 12:61–65.
107. Andorsohn F, Konzen C, Bronder E, Klimpel A, Garbe E. Citations triggered by mirtazapine. Acta Psychiatr Scand 2001; 12:61–65.
108. Paddock S, McKeon P, O’Regan M, O’Flaherty A, Patel R. Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline. J Clin Psychopharmacol 1992; 12:104–109.
109. O’Brien S, McKeon P, O’Regan M, O’Flaherty A, Patel R. Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline. J Clin Psychopharmacol 1992; 12:104–109.
110. Anisman H, Ravindran AV, Griffiths J, Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 1999; 4:182–188.
111. Marchesi C, Bertoni S, Maggini C. Major and minor depression in pregnancy. Obstet Gynecol 2009; 113:1292–1298.
112. Dodd S, Berk M. The safety of medications for the treatment of bipolar disorder during pregnancy and the puerperium. Curr Drug Saf 2006; 1:25–33.
113. Dodd S, Berk M. The pharmacology of bipolar disorder during pregnancy and breastfeeding. Expert Opin Drug Saf 2004; 3:221–229.
114. Thomas KL, Ellingrod VL. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy 2009; 29:822–831.
115. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006; 47:75–85.
116. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25:193–200.
117. Singh A. Pharmacogenomics: the potential of genetically guided prescribing. Aust Fam Physician 2007; 36:820–824.
118. Laje G, Paddock S, Manji H et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007; 164:1530–1538.
119. Malhi GS, Lagopoulos J. Making sense of neuroimaging in psychiatry. Acta Psychiatr Scand 2008; 117:100–117.
120. Loo C, Trollor J, Alonzo A, Rendina N, Kavess R. Mental health and psychiatric treatments in NSW: electroconvulsive therapy and deep brain stimulation. Australas Psychiatry 2010; 18:417–425.
121. Tiller JWG, Lyndon R.W. Electroconvulsive therapy: an Australian guide. Fitzroy, VIC: Australian Postgraduate Medicine, 2003.
122. McDermott B, Baigent M, Chanen A et al. beyondblue: expert working committee (2010) Clinical practice guidelines: Depression in adolescents and young adults. Melbourne: beyondblue: the national depression initiative, 2010. Available at URL: http://www.beyondblue.org.au/index.aspx?link_id = 6.1247&tmp = File
cDownload&fid = 1625
123. Perksy S, Reinus JF. Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity. Dig Dis Sci 2003; 48:939–944.
124. Mc Dermott B, Baigent M, Chanen A et al. beyondblue: expert working committee (2010) Clinical practice guidelines: Depression in adolescents and young adults. Melbourne: beyondblue: the national depression initiative, 2010. Available at URL: http:// www.beyondblue.org.au/index.aspx?link_id = 6.1247&tmp = File
cDownload&fid = 1625
125. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61:117–37–41.
126. Bera D, Banerjee S, Roy K, Dey S. Electroconvulsive therapy: an Australian guide. Fitzroy, VIC: Australian Postgraduate Medicine, 2003.
127. Persky S, Reinus JF. Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity. Dig Dis Sci 2003; 48:939–944.
128. Friedenberg FK, Rothstein KD. Hepatitis secondary to fluoxetine treatment. Am J Psychiatry 1996; 153:580.
S. DODD, G. S. MALHI, J. TILLER ET AL.

141. Cai Q, Benson MA, Talbot TJ, Devadas G, Swanson HJ, Olson JL, Kirchner JP. Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc 1999; 74:692–694.

142. Otani K, Kaneko S, Tasaki H, Fukushima Y. Hepatic injury caused by mianserin. BMJ 1989; 299:519.

143. Hui CK, Yuen MF, Wong WM, Lam SK, Lai CL. Mirtazapine-induced hepatotoxicity. J Clin Gastroenterol 2002; 35:270–271.

144. Adetunji B, Basil B, Mathews M, Osinowo T. Mirtazapine-associated dose-dependent and asymptomatic elevation of hepatic enzymes. Ann Pharmacother 2007; 41:359.

145. Humayun F, Shehab TM, Torek JA, Fontana RJ. A fatal case profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 2008; 4:281–285.

146. Owen RT. Agomelatine: a novel pharmacological approach to treating depression. Drugs Today (Barc) 2009; 45:599–608.

147. Hull M, Jones R, Bendall M. Fatal hepatic necrosis associated with trazodone and neuroleptic drugs. BMJ 1994; 309:378.

148. McIntyre RS, Panjwani ZD, Nguyen HT. Fatal hepatic necrosis associated with venlafaxine and trazodone therapy: a case report. Can Med Assoc J 2008; 179:1781–1784.

149. Kostrubsky SE, Strom SC, Kalgutkar AS. Inappropriate secretion of antidiuretic hormone associated with citalopram and mirtazapine. J Bone Miner Res 2008; 23:84–87.

150. Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA, Nicholson GC, Pasco JA. Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report. Am J Med Sci 2003; 326:109–111.

151. Wilkinson TJ, Begg EJ, Winter AC, Sainsbury R. Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people. Br J Clin Pharmacol 1999; 47:211–217.

152. Battaglino R, Fu J, Spate U, Ersoy U, Joe M, Sedaghat L, Stashenkov P. Serotonin regulates osteoclast differentiation through its 5-HT3 receptor. J Bone Miner Res 2004; 19:1420–1431.

153. Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH. Selective serotonin reuptake inhibitors and hyponatraemia: a review and proposed mechanisms in the elderly. J Psychopharmacol 1998; 12:396–400.

154. Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. Can Med Ass J 1996; 155:519–527.

155. Barclay TS, Lee AJ. Citalopram-associated SIADH. Ann Pharmacother 2002; 36:1558–1563.

156. van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29:S1–9.

157. Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30:1206–1227.
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Dodd, S; Malhi, GS; Tiller, J; Schweitzer, I; Hickie, I; Khoo, JP; Bassett, DL; Lyndon, B; Mitchell, PB; Parker, G; Fitzgerald, PB; Udina, M; Singh, A; Moylan, S; Giorlando, F; Doughty, C; Davey, CG; Theodoros, M; Berk, M

Title:
A consensus statement for safety monitoring guidelines of treatments for major depressive disorder

Date:
2011-09-01

Citation:
Dodd, S., Malhi, G. S., Tiller, J., Schweitzer, I., Hickie, I., Khoo, J. P., Bassett, D. L., Lyndon, B., Mitchell, P. B., Parker, G., Fitzgerald, P. B., Udina, M., Singh, A., Moylan, S., Giorlando, F., Doughty, C., Davey, C. G., Theodoros, M. & Berk, M. (2011). A consensus statement for safety monitoring guidelines of treatments for major depressive disorder. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 45 (9), pp.712-725. https://doi.org/10.3109/00048674.2011.595686.

Persistent Link:
http://hdl.handle.net/11343/264130

File Description:
Published version

License:
CC BY